Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer
Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.